Olaf Kutsch Phones & Addresses
-
5909 Southhall Rd, Birmingham, AL 35213 (205) 595-8094
Publications
Us Patents
Viral Modulators And Processes Thereof
View pageUS Patent:
20120190723, Jul 26, 2012
Filed:
Dec 14, 2011
Appl. No.:
13/325464
Inventors:
Fatah Kashanchi - Potomac MD, US
Olaf Kutsch - Birmingham AL, US
Olaf Kutsch - Birmingham AL, US
International Classification:
C12N 7/06
A61P 31/18
C12Q 1/68
A61K 31/404
C12N 15/85
A61P 31/18
C12Q 1/68
A61K 31/404
C12N 15/85
US Classification:
514418, 435238, 435455, 435 61
Abstract:
A viral modulator and process thereof. A method may include contacting one or more viral modulators to one or more biological systems. A biological system may be configured to be infected by one or more virus. A virus may include an HIV virus, a VEEV virus and/or the like. A viral modulator may include a viral inhibitor and/or a viral activator.
Latent Human Immunodeficiency Virus Reactiviation
View pageUS Patent:
20130096054, Apr 18, 2013
Filed:
May 18, 2011
Appl. No.:
13/698490
Inventors:
Olaf Kutsch - Birmingham AL, US
Michael Niederweis - Homewood AL, US
Frank Wolschendorf - Birmingham AL, US
Alexandra Duverger - Birmingham AL, US
Frederic Wagner - Birmingham AL, US
Michael Niederweis - Homewood AL, US
Frank Wolschendorf - Birmingham AL, US
Alexandra Duverger - Birmingham AL, US
Frederic Wagner - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
C07K 14/16
A61K 45/00
A61K 38/16
A61K 45/00
A61K 38/16
US Classification:
514 41, 435375, 4352521, 435 691, 530350
Abstract:
Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-κB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-κB activity without a second delayed increase in NF-κB activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). Also provided are methods of culturing the bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by bacteria, optionally with a priming agent.
Treating Mycobacterial Infection With Cu+/++ Boosting Therapeutics
View pageUS Patent:
20130324598, Dec 5, 2013
Filed:
Feb 17, 2012
Appl. No.:
13/985711
Inventors:
Olaf Kutsch - Birmingham AL, US
Frank Wolschendorf - Birmingham AL, US
Frank Wolschendorf - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
C07F 1/08
US Classification:
514499, 556 35, 435 32
Abstract:
Provided herein are methods of treating a subject with a mycobacterial infection. The methods comprise administering to the subject a Cu boosting therapeutic. Also provided are compositions comprising a Cu boosting therapeutic. Further provided are methods of screening for a Cu boosting therapeutic.
Compositions For Detection Of Latent Hiv Reactivation And Methods Of Using The Same
View pageUS Patent:
20080118494, May 22, 2008
Filed:
Sep 2, 2005
Appl. No.:
11/661881
Inventors:
Olaf Kutsch - Birmingham AL, US
Jennifer Jones - Vestavia Hills AL, US
George M. Shaw - Birmingham AL, US
David N. Levy - New York NY, US
Jennifer Jones - Vestavia Hills AL, US
George M. Shaw - Birmingham AL, US
David N. Levy - New York NY, US
International Classification:
A61K 35/76
C12N 7/00
C12N 5/06
C12Q 1/70
A61P 43/00
A61K 39/00
A61K 39/395
C12N 7/00
C12N 5/06
C12Q 1/70
A61P 43/00
A61K 39/00
A61K 39/395
US Classification:
4241301, 4352351, 4353723, 435 5, 435375, 4242781, 424 937
Abstract:
Provided herein are compositions and methods that allow for the study of HIV latency and reactivation. Further provided are compositions and methods for in vitro screening of agents for their ability to reactivate, suppress reactivation or inhibit transcription of HIV. Compositions for and methods for activating a cell are also provided herein. Further provided herein are methods of treating a subject using agents that reactivate latent HIV infection or agents that inhibit HIV transcription. Also provided herein are methods of activating a latent microbiological entity in a subject. Further provided herein are methods for enhancing an immune response in a subject and compositions used as a vaccination adjuvant. Methods of making disclosed cells and compositions are also provided herein.
Methods Of Reactivating A Latent Human Immunodeficiency Virus
View pageUS Patent:
20170014469, Jan 19, 2017
Filed:
Sep 30, 2016
Appl. No.:
15/281672
Inventors:
- Birmingham AL, US
Olaf Kutsch - Birmingham AL, US
Olaf Kutsch - Birmingham AL, US
International Classification:
A61K 38/05
A61K 31/145
A61K 31/22
A61K 38/08
A61K 31/365
A61K 31/145
A61K 31/22
A61K 38/08
A61K 31/365
Abstract:
Provided herein are methods of reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell or subject. The methods include contacting the cell with or administering to the subject one or more proteasome inhibitors, and contacting the cell with or administering to the subject one or more reactivating agents. Also provided are methods of treating an HIV infection in a subject. The methods include administering to the subject one or more proteasome inhibitors, administering to the subject one or more reactivating agents and administering to the subject one or more anti-retroviral agents.
Methods Of Reactivating A Latent Human Immunodeficiency Virus
View pageUS Patent:
20150216926, Aug 6, 2015
Filed:
Jun 26, 2014
Appl. No.:
14/316144
Inventors:
- Birmingham AL, US
Olaf Kutsch - Birmingham AL, US
Olaf Kutsch - Birmingham AL, US
International Classification:
A61K 38/07
A61K 31/145
A61K 38/15
A61K 31/22
A61K 45/06
A61K 38/05
A61K 31/365
A61K 31/145
A61K 38/15
A61K 31/22
A61K 45/06
A61K 38/05
A61K 31/365
Abstract:
Provided herein are methods of reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell or subject. The methods include contacting the cell with or administering to the subject one or more proteasome inhibitors, and contacting the cell with or administering to the subject one or more reactivating agents. Also provided are methods of treating an HIV infection in a subject. The methods include administering to the subject one or more proteasome inhibitors, administering to the subject one or more reactivating agents and administering to the subject one or more anti-retroviral agents.